Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
about
Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatmentThe Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells.Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.Differential regulation of myeloid leukemias by the bone marrow microenvironment.Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemiaGambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction.Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.Chronic myeloid leukemia stem cells and developing therapies.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.Stem cell persistence in chronic myeloid leukemia.Where are we going with CML research?Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.The anti-leukemic effect of carnosic acid combined with adriamycin in a K562/A02/SCID leukemia mouse model.Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.A "RANning" leap with "XPOrt" into TKI resistanceRole of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance.Leukemia stem cells.
P2860
Q33828445-D9FA3A6F-A247-40C1-A0E3-9657F2B23786Q34750582-AE3A8769-CB00-4B49-8514-1D8F0FA54AADQ35171271-E78D5D83-E989-44A5-95E4-A670CE5F1E78Q35510549-30B90A91-AF5D-4940-B696-5C63ED931F6CQ35553345-9A28AF37-A168-464D-B546-D483AB38D17EQ36129530-4BF6C3CD-F171-4F8C-A241-E42174E6FA33Q36691554-3B50D665-6322-46D6-A4A0-FDC39AB76D17Q36755221-416990D8-7D96-44B3-A841-FF846863FF9DQ37200863-5D215BC5-E4BE-4D07-AAC7-7FDE03F8354CQ37308308-2026DC20-1AF0-48A4-96F4-A29A7EA928E5Q37440054-18231C6E-C518-43A0-BEA8-705974DA9ECBQ37440458-1C961688-D31E-4D7F-911C-67B26721FC03Q37610733-65FB58DE-7564-4D46-B32A-D578360B7A9BQ37614613-515047DE-3AC9-495C-8401-75CD11985847Q37697852-288535BC-A956-4F3A-8629-1773106A03A1Q37709023-856D9EE5-467F-49B6-B6EA-93960C6EAB5BQ37767357-BA04C168-D031-4490-9C60-22FF8626BDBAQ37836936-E81859CA-C784-43AA-8C13-B5B9846CE315Q38866390-03BCA2B3-195A-414A-8394-864DB2233501Q40817591-035E91F3-A496-4BA7-AD60-18BA0A67F007Q40817656-5E9E062F-539C-4E8B-84BA-4B0E108C2148Q41335233-54161A0F-53D7-4EDE-91DC-30BC683FC8CBQ41970416-7D93722C-12BE-4DD6-BA31-252712939738Q42113263-50847A94-0AB6-4426-B76D-18638580E56EQ42178391-1FAAF020-C2E9-477B-B9B9-BC42BDE96886Q42710172-F6490D2A-CCAA-42B4-B304-1987E31D3D25Q45052577-FEA7B71E-6414-4066-BB7D-8176A8E7E023Q53293069-272ECEC1-41C3-477A-BD9F-B0150E694C61
P2860
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Bortezomib induces apoptosis i ...... d NOD/SCID repopulating cells.
@ast
Bortezomib induces apoptosis i ...... d NOD/SCID repopulating cells.
@en
type
label
Bortezomib induces apoptosis i ...... d NOD/SCID repopulating cells.
@ast
Bortezomib induces apoptosis i ...... d NOD/SCID repopulating cells.
@en
prefLabel
Bortezomib induces apoptosis i ...... d NOD/SCID repopulating cells.
@ast
Bortezomib induces apoptosis i ...... d NOD/SCID repopulating cells.
@en
P2093
P2860
P1433
P1476
Bortezomib induces apoptosis i ...... nd NOD/SCID repopulating cells
@en
P2093
Alexandra E Irvine
Elaine K Allan
Francesca Pellicano
Lisa Crawford
Nicholas B Heaney
Ravi Bhatia
Syed M A Kazmi
P2860
P304
P356
10.1182/BLOOD-2008-06-164582
P407
P577
2010-01-12T00:00:00Z